Vanda Pharmaceuticals Receives EMA Positive Opinion for Orphan Drug Designation of Imsidolimab

Vanda Pharmaceuticals announced on July 16, 2026, that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products has issued a positive opinion recommending orphan drug designation for imsidolimab, the company's investigational antibody treatment, for generalized pustular psoriasis (GPP). This represents the first time the EMA has granted this designation for a GPP treatment in the European Union (EU).

Generalized pustular psoriasis is a severe, chronic, and potentially life-threatening inflammatory skin disease. It is genetically and clinically distinct from plaque psoriasis and driven by dysregulation of the interleukin-36 (IL-36) signaling pathway. The condition is characterized by widespread pustular eruptions and systemic inflammation, which can lead to serious complications and increased mortality.

Imsidolimab is a high-affinity humanized antibody designed to inhibit IL-36 receptor signaling. It addresses the deficiency in the endogenous IL-36 receptor antagonist commonly observed in patients with GPP, targeting the underlying cause of the disease.

Orphan drug designation is granted by the EMA to medicines intended for rare conditions affecting fewer than 5 in 10,000 people in the EU. Benefits include protocol assistance, reduced regulatory fees, and market exclusivity for a period following approval.

The company is also awaiting a decision from the U.S. Food and Drug Administration (FDA) on its Biologics License Application for imsidolimab for GPP, with a target action date set for December 12, 2026. Similar regulatory recognitions have previously been granted in the United States and Japan.